Engineered Veterinary Vectored Immunotherapy and Vaccines: EVVIVAX

Just open a Bet365 account today and make a deposit http://abonuscode.co.uk Make a deposit of £10-£200 and then enter the 10-digit bonus code

Rome, 27 January 2020 - Takis and Evvivax, two biotechnology companies present in the science park of Castel Romano, Rome announce their commitment for the development of innovative vaccines against 2019-nCoV, the new coronavirus originating in Wuhan, China. To date, the virus has caused 81 deaths and over 2,800 known infections and is rapidly expanding in various countries.


"This is a worldwide emergency to which Takis researchers can and must contribute" - says Luigi Aurisicchio, CEO / CSO of the two companies - "We will immediately make available our skills gained for the development of vaccines against Cancer and other infectious diseases to fight the spread of this coronavirus ". Takis and Evvivax have developed vaccines based on genetic technologies capable of inducing powerful immune responses. "Our technologies are based on genetic engineering techniques and on the use of viruses and DNA fragments that can be used both for gene therapy and for vaccination" - says Emanuele Marra, Director of the Infectious Diseases Area at Takis. “To obtain antibodies capable of neutralizing pathogens, it is essential to use particularly effective technologies. At Takis, thanks to genetic vaccination, we have generated dozens of antibodies capable of neutralizing viruses and pathogenic bacteria "- continues Giuseppe Roscilli, Antibody Area Director. "In various clinical studies conducted in Italy and the USA, our veterinary vaccines have induced a powerful immune response and prolonged the survival of dogs with cancer, which like us humans develop it with high frequency. Even against zoonoses, that is, infectious diseases that are transmitted from animals to humans and vice versa, we can use the same type of approach. "- declares Dr. Antonella Conforti, Director at Evvivax.

Genetic vaccination is therefore the basis for the development of the 2019-nCoV vaccine at Takis. “Coronavirus biology and the availability of the 2019-nCoV genome sequence are all the information we need for vaccine design. The development of the methods and the experimentation will be fundamental to get to human clinical trials as soon as possible "- says Fabio Palombo, Immunology and Cancer Vaccines Area – NeoMatrix Director.

"Thanks to the experience of our scientists, Takis and Evvivax are technologically competitive at an international level and can make their contribution to this Health emergency with the internal resources currently available. However, scientific research requires important investments and it is essential to obtain financing and / or collaborations with large companies as soon as possible that allow us to develop the 2019-nCoV vaccine as quickly as necessary. "- concludes Luigi Aurisicchio.
The race against the virus has started.

For more information: www.takisbiotech.it and www.evvivax.com

Coronavirus 2019 nCoV with Transmission Electron Microscopy
Visualization of 2019-nCoV with Transmission Electron Microscopy.
Negative-stained 2019-nCoV particles are shown in Panel A, and 2019-nCoV particles in the human airway epithelial cell ultrathin sections are shown in Panel B.

 

Just open a Bet365 account today and make a deposit http://abonuscode.co.uk Make a deposit of £10-£200 and then enter the 10-digit bonus code

Tumor Reduction Demonstrated In Vivo Using Two Linear DNA Vaccines in Animal Models

Tumor Reduction

STONY BROOK, N.Y., September 19, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its majority-owned subsidiary focused on next-generation biotherapeutics, and its collaborators Takis/Evvivax have completed pre-clinical animal studies of two vaccine candidates produced with linear DNA. Tests of both vaccines in mouse models demonstrated their ability to eliminate tumors in vivo, and to potentially prevent initial occurrence.

Evvivax S.R.L. designed a synthetic gene sequence to produce immunity in companion animals, directed against the protein telomerase (TERT), which is overexpressed in 85% of all mammalian cancers, whereas Takis S.R.L. designed a neoantigen-based cancer vaccine (TK), as a proof-of-concept of personalized immunology. For the studies, the TERT and TK based vaccines were produced in linear DNA form by LineaRx. Here is a summary of the recently completed studies performed in vivo:

Previous results from Phase 1 of the collaboration’s Joint Development Agreement (JDA) confirmed immunogenicity in mice that were vaccinated with linear DNA against the human protein telomerase. The results reported herein are from the Phase 2 of the JDA using mice implanted with murine colon cancer.
In the prophylactic use of the telomerase vaccine, wherein vaccination is done before addition of tumor cell lines to the mice, transplanted tumors were cleared within 10 days.
In the therapeutic application using either TERT or TK linear DNA vaccine application, cancer cells were introduced and allowed to grow before administration of the vaccine. The successful reduction of total tumor mass was accomplished in conjunction with antibodies that targeted PD-1 and CTLA4. These antibodies, known as Checkpoint Inhibitors, are commonly used in oncology strategies that rely upon immunotherapy. In this setting the tumor cells were reduced significantly within 30 days.
The strategy of the Takis TK neoantigen vaccine uses unique multiple-target antigenic epitopes that have been identified from the tumor of a human patient. The linear DNA can utilize the genes for several of the most effective universal antigens such as TERT, or neoantigens that are more personalized to the patient.

“We know that immune system has a key role in fighting cancer” said Dr. Luigi Aurisicchio, CEO of Takis/Evvivax. “Thanks to a deep knowledge of cancer immunobiology and cutting-edge vaccination technologies we have now the tools to provide new therapies to our pet friends and human patients.”

For more information please see the Press Release from Applied DNA Sciences adnas

 

Just open a Bet365 account today and make a deposit http://abonuscode.co.uk Make a deposit of £10-£200 and then enter the 10-digit bonus code

 University Hospital for Companion Animals

Our CEO/CSO Luigi Aurisicchio flew to Copenaghen to present promising results about electrochemotherapy at the University Hospital for Companion Animals.

Electrochemotherapy (ECT) is an approved and efficacious treatment for local control of cutaneous and subcutaneous tumor nodules, although less effective against distant or inaccessible metastasis.

In addition, preliminary evidences suggest that ECT can activate the immune system. We therefore investigated the synergic effect of ECT and DNA Electro-Gene Transfer (DNA-EGT) in both mice and dogs by means of a clinically validated device for Veterinary electroporation called Vet-ePorator. In particular, we explored the combination of our vaccine Erb-eVax and ECT in dogs with metastatic breast cancer or osteosarcoma, with excellent results in terms of both tumor control and immune response against Tumor Associated antigens.

Our findings provide new data on tumor immunobiology and most importantly improve the efficacy of ECT and may open up novel immunotherapeutic approaches.

We are pleased to share these data that summarize the best of our technology and make a significant impact on patients’ survival and quality of life.

 

Just open a Bet365 account today and make a deposit http://abonuscode.co.uk Make a deposit of £10-£200 and then enter the 10-digit bonus code

 

Flyer A4 Meeting Vitares 2019 Bn

Evvivax is glad to sponsor the first Vitares Annual Congress, which is also the first Italian One Health meeting focusing on Cancer Immunotherapy.

This meeting brings together Basic research, Veterinary and Human Medicine Scientists involved in the field of Immunology, Oncology and Education, aiming at creating networks of collaboration. Internationally renowned scientists from Italy and abroad will provide the State of the Art and present their most recent data in a highly stimulating scientific environment.

Public health initiatives such as One Health demonstrate the growing awareness of the fact that animal and human health are strongly interconnected with each other and with the environment. Zoonotic pathogens and Cancer represent a direct hazard to Veterinary and Human Health”, said Luigi Aurisicchio, CEO/CSO at Takis and president at Vitares.

Looking forward to meeting you in Rome!

Just open a Bet365 account today and make a deposit http://abonuscode.co.uk Make a deposit of £10-£200 and then enter the 10-digit bonus code

 

EVVIVAX conference veterinary vaccinology

Dr. Antonella Conforti represents EVVIVAX at the fifth UK & International Veterinary Vaccinology Network Conference. Topics will range from vaccine commercialisation to antigen discovery, with scientists from all over the world delivering speeches about vaccine research.

EVVIVAX has expertise in genetic cancer vaccines for pets and is committed to developing new therapeutic strategies with strong translational potential. We cannot miss this appointment, where innovative approaches and incoming challenges in veterinary vaccinology will be addressed, with the awareness that fighting animal diseases will also affect men’s health.

This year, we are plenty of ideas to further expand our research activities: we are excited to share our knowledge and look forward opportunities to network and form new collaborations in London!

ABOUT THE VETERINARY VACCINOLOGY NETWORK

EVVIVAX conference veterinary vaccinology2

The Veterinary Vaccinology Network is a multidisciplinary community who aims to address the unmet needs in veterinary vaccinology in the fight against animal diseases and consequently those that have the potential to spread to humans. The network aims to enhance collaborations between scientific researchers, industry, policy makers and regulators to design, develop and deliver safe and effective next-generation vaccines against new and (re)-emerging diseases.

See more at http://www.vetvaccnet.ac.uk/uk-and-international-veterinary-vaccinology-network-conference-2019

Evvivax News